DP
HAE icon

Dearborn Partners’s Haemonetics HAE Stock Holding History

Dearborn Partners’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-13,095
Closed -$588K – 237
2015
Q1 		$588K Sell
13,095
-3,070
-19% -$128K 0.05% 201
2014
Q4 		$605K Sell
16,165
-570
-3% -$20.9K 0.06% 200
2014
Q3 		$584K Buy
16,735
+3,670
+28% +$131K 0.06% 202
2014
Q2 		$461K Buy
13,065
+3,105
+31% +$104K 0.05% 215
2014
Q1 		$325K Hold
9,960
– – 0.04% 239
2013
Q4 		$420K Sell
9,960
-600
-6% -$24.7K 0.05% 217
2013
Q3 		$421K Hold
10,560
– – 0.06% 217
2013
Q2 		$437K Buy
+10,560
New +$428K 0.06% 210

Other funds holding HAE

Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WHG
Westwood Holdings Group Dallas, Texas $13.3B AUM 29.38% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BCIM
Black Creek Investment Management Toronto, Ontario, Canada $1.78B AUM 5.83% 1-Year Est. Return

Dearborn Partners's HAE Position: Q2 2015 in Review

Dearborn Partners sold out of Haemonetics (HAE) in Q2 2015, closing a stake of 13,095 shares — an estimated $588K sold.

Dearborn Partners first reported a position in HAE in Q2 2013 and held it in 8 quarters. The position peaked at $605K in Q4 2014. 181 funds tracked by Wall St. Rank hold HAE as of Q2 2015.

  • Dearborn Partners reported no remaining Haemonetics position as of Q2 2015 after selling out during the quarter.
  • Dearborn Partners sold 13,095 Haemonetics shares in Q2 2015, an estimated $588K.
  • Dearborn Partners first reported a position in Haemonetics in Q2 2013 and held it in 8 quarters.
  • Dearborn Partners's Haemonetics position peaked at $605K in Q4 2014.
  • 181 funds tracked by Wall St. Rank held Haemonetics as of Q2 2015.

Based on Dearborn Partners's 13F filing for Q2 2015, filed 13 Aug 2015.